C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.51 AUD Market Closed
Market Cap: 167.8m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Intrinsic Value

The intrinsic value of one CYC stock under the Base Case scenario is 2.04 AUD. Compared to the current market price of 1.51 AUD, Cyclopharm Ltd is Undervalued by 26%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CYC Intrinsic Value
2.04 AUD
Undervaluation 26%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
Cyclopharm Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
CYC
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for CYC cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about CYC?
Bearish
Neutral
Bullish

Fundamental Analysis

1.51 AUD
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Cyclopharm Ltd
AU
Health Care
Market Cap
167.8m AUD
IPO
Jan 18, 2007
Employees
48
Australia
Market Cap
167.8m AUD
Industry
Health Care
IPO
Jan 18, 2007
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Cyclopharm Ltd

Provide an overview of the primary business activities
of Cyclopharm Ltd.

What unique competitive advantages
does Cyclopharm Ltd hold over its rivals?

What risks and challenges
does Cyclopharm Ltd face in the near future?

Has there been any significant insider trading activity
in Cyclopharm Ltd recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cyclopharm Ltd.

Provide P/S
for Cyclopharm Ltd.

Provide P/E
for Cyclopharm Ltd.

Provide P/OCF
for Cyclopharm Ltd.

Provide P/FCFE
for Cyclopharm Ltd.

Provide P/B
for Cyclopharm Ltd.

Provide EV/S
for Cyclopharm Ltd.

Provide EV/GP
for Cyclopharm Ltd.

Provide EV/EBITDA
for Cyclopharm Ltd.

Provide EV/EBIT
for Cyclopharm Ltd.

Provide EV/OCF
for Cyclopharm Ltd.

Provide EV/FCFF
for Cyclopharm Ltd.

Provide EV/IC
for Cyclopharm Ltd.

Show me price targets
for Cyclopharm Ltd made by professional analysts.

What are the Revenue projections
for Cyclopharm Ltd?

How accurate were the past Revenue estimates
for Cyclopharm Ltd?

What are the Net Income projections
for Cyclopharm Ltd?

How accurate were the past Net Income estimates
for Cyclopharm Ltd?

What are the EPS projections
for Cyclopharm Ltd?

How accurate were the past EPS estimates
for Cyclopharm Ltd?

What are the EBIT projections
for Cyclopharm Ltd?

How accurate were the past EBIT estimates
for Cyclopharm Ltd?

Compare the revenue forecasts
for Cyclopharm Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cyclopharm Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cyclopharm Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cyclopharm Ltd compared to its peers.

Compare the P/E ratios
of Cyclopharm Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Cyclopharm Ltd with its peers.

Analyze the financial leverage
of Cyclopharm Ltd compared to its main competitors.

Show all profitability ratios
for Cyclopharm Ltd.

Provide ROE
for Cyclopharm Ltd.

Provide ROA
for Cyclopharm Ltd.

Provide ROIC
for Cyclopharm Ltd.

Provide ROCE
for Cyclopharm Ltd.

Provide Gross Margin
for Cyclopharm Ltd.

Provide Operating Margin
for Cyclopharm Ltd.

Provide Net Margin
for Cyclopharm Ltd.

Provide FCF Margin
for Cyclopharm Ltd.

Show all solvency ratios
for Cyclopharm Ltd.

Provide D/E Ratio
for Cyclopharm Ltd.

Provide D/A Ratio
for Cyclopharm Ltd.

Provide Interest Coverage Ratio
for Cyclopharm Ltd.

Provide Altman Z-Score Ratio
for Cyclopharm Ltd.

Provide Quick Ratio
for Cyclopharm Ltd.

Provide Current Ratio
for Cyclopharm Ltd.

Provide Cash Ratio
for Cyclopharm Ltd.

What is the historical Revenue growth
over the last 5 years for Cyclopharm Ltd?

What is the historical Net Income growth
over the last 5 years for Cyclopharm Ltd?

What is the current Free Cash Flow
of Cyclopharm Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cyclopharm Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cyclopharm Ltd

Current Assets 47.1m
Cash & Short-Term Investments 27.6m
Receivables 8.3m
Other Current Assets 11.2m
Non-Current Assets 17m
PP&E 10.4m
Intangibles 5.8m
Other Non-Current Assets 833.7k
Current Liabilities 10.7m
Accounts Payable 6.1m
Other Current Liabilities 4.7m
Non-Current Liabilities 5.8m
Long-Term Debt 4.7m
Other Non-Current Liabilities 1.1m
Efficiency

Earnings Waterfall
Cyclopharm Ltd

Revenue
29m AUD
Cost of Revenue
-10.2m AUD
Gross Profit
18.8m AUD
Operating Expenses
-27.6m AUD
Operating Income
-8.8m AUD
Other Expenses
-541k AUD
Net Income
-9.3m AUD

Free Cash Flow Analysis
Cyclopharm Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CYC Profitability Score
Profitability Due Diligence

Cyclopharm Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
26/100
Profitability
Score

Cyclopharm Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

CYC Solvency Score
Solvency Due Diligence

Cyclopharm Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Negative Net Debt
99/100
Solvency
Score

Cyclopharm Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYC Price Targets Summary
Cyclopharm Ltd

Wall Street analysts forecast CYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYC is 2.75 AUD with a low forecast of 2.73 AUD and a high forecast of 2.84 AUD.

Lowest
Price Target
2.73 AUD
81% Upside
Average
Price Target
2.75 AUD
82% Upside
Highest
Price Target
2.84 AUD
88% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CYC?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CYC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CYC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

See Also

Discover More
What is the Intrinsic Value of one CYC stock?

The intrinsic value of one CYC stock under the Base Case scenario is 2.04 AUD.

Is CYC stock undervalued or overvalued?

Compared to the current market price of 1.51 AUD, Cyclopharm Ltd is Undervalued by 26%.

Back to Top